-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, The British Medical Journal (The BMJ) published international clinical practice guidelines, recommending SGLT-2 inhibitors or GLP-1 receptor agonists for adult type 2 diabetes, focusing on patients with different heart and kidney risks, and evaluating The benefits and harms of these two types of drugs combined with conventional diagnosis and treatment (life>
The guidelines are jointly formulated by clinical and methodological experts from more than ten countries around the world.
People with type 2 diabetes have an increased risk of cardiovascular disease, kidney disease, and other complications.
SGLT-2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide 1) receptor agonists are two relatively new types of hypoglycemic agents, which are usually used for blood glucose levels after metformin treatment.
SGLT-2 inhibitors are a class of oral hypoglycemic drugs, including empagliflozin, canagliflozin, dapagliflozin and etogliflozin.
The guidelines stratify the risk of heart and kidney complications in patients with type 2 diabetes, and the relevant criteria are as follows:
Cardiovascular risk factors include: age> 60 years, male, Asian, African or Hispanic, family history of cardiovascular disease or kidney disease, poor control of glycosylated hemoglobin (>6.
Based on the latest evidence-based medical evidence, for patients with different risk stratifications, the guidelines have evaluated the risks and benefits of using or not using these two types of drugs on the basis of existing prescriptions, and finally formed the following recommendations.
With ≤3 cardiovascular risk factors, but no CVD or CKD: It is not recommended to initiate SGLT-2 inhibitors or GLP-1 receptor agonist therapy (weak recommendation).
Reference
[1] Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC, Rodriguez-Gutierrez R, et al.
[2] The International Clinical Practice Guidelines for Diabetes developed by West China Hospital is released.
